Back to top

Image: Bigstock

Masimo Corporation

Read MoreHide Full Article

Masimo Corporation reported solid first-quarter of 2017 results, beating the Zacks Consensus Estimate for both the counts. Over the past one year, Masimo has outperformed the broader industry with respect to price. Going forward, we believe the company's expanding product portfolio is a key catalyst. Wider adoption of its non-invasive patient monitoring technology will help the company gain market traction. Masimo’s SET pulse oximetry business represents considerable growth opportunities in international markets. Moreover, the FDA 510 (k) approval for the Radius 7 wearable and the O3 regional oximetry device are significant positives. On the flipside, unsatisfactory performance by the Rainbow product segment in the first quarter is a concern. Masimo also looks a tad bit expensive at the moment. Furthermore, the company faces fierce competition from OEM distributors and medical devices bigwigs that might mar its top line over the long haul.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Masimo Corporation (MASI) - free report >>

Published in